Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

Yehuda Z. Patt; Manal M. Hassan; Richard D. Lozano; Lee M. Ellis; J. Andrew Peterson; Kimberly A. Waugh; Aman U. Buzdar; Christine F. Wogan

doi:10.1097/00000421-200006000-00023

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

Yehuda Z. Patt, Manal M. Hassan, Richard D. Lozano, Lee M. Ellis, J. Andrew Peterson, Kimberly A. Waugh, Aman U. Buzdar, Christine F. Wogan

Research output: Contribution to journal › Article › peer-review

63 Scopus citations

Abstract

Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

Original language	English (US)
Pages (from-to)	319-321
Number of pages	3
Journal	American Journal of Clinical Oncology: Cancer Clinical Trials
Volume	23
Issue number	3
DOIs	https://doi.org/10.1097/00000421-200006000-00023
State	Published - 2000

Keywords

Angiogenesis
Hepatocellular carcinoma
Thalidomide

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1097/00000421-200006000-00023

Cite this

@article{f0ff2d9f6e7542eab6cb569b17601683,

title = "Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide",

abstract = "Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.",

keywords = "Angiogenesis, Hepatocellular carcinoma, Thalidomide",

author = "Patt, {Yehuda Z.} and Hassan, {Manal M.} and Lozano, {Richard D.} and Ellis, {Lee M.} and Peterson, {J. Andrew} and Waugh, {Kimberly A.} and Buzdar, {Aman U.} and Wogan, {Christine F.}",

year = "2000",

doi = "10.1097/00000421-200006000-00023",

language = "English (US)",

volume = "23",

pages = "319--321",

journal = "American Journal of Clinical Oncology: Cancer Clinical Trials",

issn = "0277-3732",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

AU - Patt, Yehuda Z.

AU - Hassan, Manal M.

AU - Lozano, Richard D.

AU - Ellis, Lee M.

AU - Peterson, J. Andrew

AU - Waugh, Kimberly A.

AU - Buzdar, Aman U.

AU - Wogan, Christine F.

PY - 2000

Y1 - 2000

N2 - Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

AB - Thalidomide, a sedative agent previously associated with severe fetal malformations, has anti-angiogenic activity. We describe the antitumor effects of thalidomide in a patient with hepatocellular carcinoma that was refractory to systemic and intraarterial therapy.

KW - Angiogenesis

KW - Hepatocellular carcinoma

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=0034444007&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034444007&partnerID=8YFLogxK

U2 - 10.1097/00000421-200006000-00023

DO - 10.1097/00000421-200006000-00023

M3 - Article

C2 - 10857902

AN - SCOPUS:0034444007

SN - 0277-3732

VL - 23

SP - 319

EP - 321

JO - American Journal of Clinical Oncology: Cancer Clinical Trials

JF - American Journal of Clinical Oncology: Cancer Clinical Trials

IS - 3

ER -

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this